Search

Your search keyword '"Angelopoulou, Maria K."' showing total 37 results
Start Over Author "Angelopoulou, Maria K." Database OAIster
37 results on '"Angelopoulou, Maria K."'

1. Very Early Onset of Therapy-Related Acute Myeloid Leukemia with 11q23 Rearrangement Presenting with Unusual PET Findings after R-DA-EPOCH for Primary Mediastinal Large B-Cell Lymphoma

Author

Chatzidimitriou, Chrysovalantou Rondogianni, Phivi Arapaki, Maria Liaskas, Athanasios Plata, Eleni Angelopoulou, Maria K. Tsirigotis, Panagiotis Vassilakopoulos, Theodoros P. and Chatzidimitriou, Chrysovalantou Rondogianni, Phivi Arapaki, Maria Liaskas, Athanasios Plata, Eleni Angelopoulou, Maria K. Tsirigotis, Panagiotis Vassilakopoulos, Theodoros P.

Abstract

Background: R-DA-EPOCH is an effective regimen for PMLBCL, which permits the omission of consolidative radiotherapy in the majority of patients. Patient: We describe a 27-year-old female patient, who achieved a complete remission after treatment with six cycles of R-DA-EPOCH (up to the final level). At 6 months after the end of treatment, PET/CT revealed an unexpected, diffusely increased (18)FDG uptake by the bone marrow. Simultaneously, pancytopenia with monocytosis was observed. Result: The patient was diagnosed with therapy-related myelodysplastic syndrome, which rapidly evolved into acute myeloid leukemia (t-MDS/AML) with MLL rearrangements. She achieved a complete remission after induction therapy, received an allogenic transplant and remains disease-free 2 years later. Conclusions: The extremely early onset of t-MDS/AML, together with the unexpected PET/CT findings make this case unique and highlights the need for the accurate estimation of the possible dose-dependent risk of t-MDS/AML after R-DA-EPOCH in the real-life setting in patients with PMLBCL.

Published
2022

2. Progressive Multifocal Leukoencephalopathy Following Treatment With Obinutuzumab in a Patient With Non-Hodgkin Follicular Lymphoma: A Case Report

Author

Diavati, Stavrianna Asimakopoulos, V, John Galopoulos, Dimitrios and Konstantinou, Iliana Argyrakos, Theodore Toulas, Panagiotis and Vassilakopoulos, Theodoros P. Konstantopoulos, Kostas and Angelopoulou, Maria K. and Diavati, Stavrianna Asimakopoulos, V, John Galopoulos, Dimitrios and Konstantinou, Iliana Argyrakos, Theodore Toulas, Panagiotis and Vassilakopoulos, Theodoros P. Konstantopoulos, Kostas and Angelopoulou, Maria K.

Published
2021

3. Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP

Author

Vassilakopoulos, Theodoros P. Michail, Michail Papageorgiou, Sotirios Kourti, Georgia Angelopoulou, Maria K. Panitsas, Fotios Sachanas, Sotirios Kalpadakis, Christina Katodritou, Eirini Leonidopoulou, Theoni Kotsianidis, Ioannis and Hatzimichael, Eleftheria Kotsopoulou, Maria Dimou, Maria and Variamis, Eleni Boutsis, Dimitrios Terpos, Evangelos and Dimopoulou, Maria N. Karakatsanis, Stamatios Michalis, Eurydiki and Karianakis, George Tsirkinidis, Pantelis Vadikolia, Chryssa and Poziopoulos, Christos Pigaditou, Anna Vrakidou, Effimia and Economopoulos, Theophanis Kyriazopoulou, Lydia Siakantaris, Marina P. Kyrtsonis, Marie-Christine Symeonidis, Argyris and Anargyrou, Konstantinos Papaioannou, Maria Hatjiharissi, Evdoxia and Vervessou, Elissavet Tsirogianni, Maria Palassopoulou, Maria and Gainaru, Gabriella Stefanoudaki, Ekaterini Zikos, Panayiotis and Tsirigotis, Panayiotis Tsourouflis, Gerasimos and Assimakopoulou, Theodora Konstantinidou, Pavlina Papadaki, Helen A. Megalakaki, Katerina Dimopoulos, Meletios-Athanasios and Pappa, Vassiliki Karmiris, Themis Roussou, Paraskevi and Panayiotidis, Panayiotis Konstantopoulos, Kostas Pangalis, Gerassimos A. and Vassilakopoulos, Theodoros P. Michail, Michail Papageorgiou, Sotirios Kourti, Georgia Angelopoulou, Maria K. Panitsas, Fotios Sachanas, Sotirios Kalpadakis, Christina Katodritou, Eirini Leonidopoulou, Theoni Kotsianidis, Ioannis and Hatzimichael, Eleftheria Kotsopoulou, Maria Dimou, Maria and Variamis, Eleni Boutsis, Dimitrios Terpos, Evangelos and Dimopoulou, Maria N. Karakatsanis, Stamatios Michalis, Eurydiki and Karianakis, George Tsirkinidis, Pantelis Vadikolia, Chryssa and Poziopoulos, Christos Pigaditou, Anna Vrakidou, Effimia and Economopoulos, Theophanis Kyriazopoulou, Lydia Siakantaris, Marina P. Kyrtsonis, Marie-Christine Symeonidis, Argyris and Anargyrou, Konstantinos Papaioannou, Maria Hatjiharissi, Evdoxia and Vervessou, Elissavet Tsirogianni, Maria Palassopoulou, Maria and Gainaru, Gabriella Stefanoudaki, Ekaterini Zikos, Panayiotis and Tsirigotis, Panayiotis Tsourouflis, Gerasimos and Assimakopoulou, Theodora Konstantinidou, Pavlina Papadaki, Helen A. Megalakaki, Katerina Dimopoulos, Meletios-Athanasios and Pappa, Vassiliki Karmiris, Themis Roussou, Paraskevi and Panayiotidis, Panayiotis Konstantopoulos, Kostas Pangalis, Gerassimos A.

Abstract

Background R-CHOP can cure approximately 75% of patients with primary mediastinal large B-cell lymphoma (PMLBCL), but prognostic factors have not been sufficiently evaluated yet. R-da- EPOCH is potentially more effective but also more toxic than R-CHOP. Reliable prognostic classification is needed to guide treatment decisions. Materials and Methods We analyzed the impact of clinical prognostic factors on the outcome of 332 PMLBCL patients <= 65 years treated with R-CHOP +/- radiotherapy in a multicenter setting in Greece and Cyprus. Results With a median follow-up of 69 months, 5-year freedom from progression (FFP) was 78% and 5-year lymphoma specific survival (LSS) was 89%. On multivariate analysis, extranodal involvement (E/IV) and lactate dehydrogenase (LDH) >= 2 times upper limit of normal (model A) were significantly associated with FFP; E/IV and bulky disease (model B) were associated with LSS. Both models performed better than the International Prognostic Index (IPI) and the age-adjusted IPI by Harrel’s C rank parameter and Akaike information criterion. Both models A and B defined high-risk subgroups (13%-27% of patients [pts]) with approximately 19%-23% lymphoma-related mortality. They also defined subgroups composing approximately one-fourth or one-half of the patients, with 11% risk of failure and only 1% or 4% 5-year lymphoma-related mortality. Conclusion The combination of E/IV with either bulky disease or LDH >= 2 times upper limit of normal defined high-risk but not very-high-risk subgroups. More importantly, their absence defined subgroups comprising approximately one-fourth or one-half of the pts, with 11% risk of failure and minimal lymphoma-related mortality, who may not need more intensive treatment such as R-da-EPOCH. Implications for Practice By analyzing the impact of baseline clinical characteristics on outcomes of a large cohort of patients with primary mediastinal large B-cell lymphoma homogeneously treated with R-CHOP with or witho

Published
2021

4. Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP

Author

Vassilakopoulos, Theodoros P Michail, Michail Papageorgiou, Sotirios Kourti, Georgia Angelopoulou, Maria K Panitsas, Fotios Sachanas, Sotirios Kalpadakis, Christina Katodritou, Eirini Leonidopoulou, Theoni others and Vassilakopoulos, Theodoros P Michail, Michail Papageorgiou, Sotirios Kourti, Georgia Angelopoulou, Maria K Panitsas, Fotios Sachanas, Sotirios Kalpadakis, Christina Katodritou, Eirini Leonidopoulou, Theoni others

Published
2021

5. Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies

Author

Vassilakopoulos, Theodoros P Papageorgiou, Sotirios G Angelopoulou, Maria K Chatziioannou, Sophia Prassopoulos, Vassilios Karakatsanis, Stamatios Arapaki, Maria Mellios, Zois Sachanas, Sotirios Kalpadakis, Christina others and Vassilakopoulos, Theodoros P Papageorgiou, Sotirios G Angelopoulou, Maria K Chatziioannou, Sophia Prassopoulos, Vassilios Karakatsanis, Stamatios Arapaki, Maria Mellios, Zois Sachanas, Sotirios Kalpadakis, Christina others

Published
2021

6. Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies

Author

Vassilakopoulos, Theodoros P Papageorgiou, Sotirios G Angelopoulou, Maria K Chatziioannou, Sophia Prassopoulos, Vassilios Karakatsanis, Stamatios Arapaki, Maria Mellios, Zois Sachanas, Sotirios Kalpadakis, Christina others and Vassilakopoulos, Theodoros P Papageorgiou, Sotirios G Angelopoulou, Maria K Chatziioannou, Sophia Prassopoulos, Vassilios Karakatsanis, Stamatios Arapaki, Maria Mellios, Zois Sachanas, Sotirios Kalpadakis, Christina others

Published
2021

7. Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP

Author

Vassilakopoulos, Theodoros P Michail, Michail Papageorgiou, Sotirios Kourti, Georgia Angelopoulou, Maria K Panitsas, Fotios Sachanas, Sotirios Kalpadakis, Christina Katodritou, Eirini Leonidopoulou, Theoni others and Vassilakopoulos, Theodoros P Michail, Michail Papageorgiou, Sotirios Kourti, Georgia Angelopoulou, Maria K Panitsas, Fotios Sachanas, Sotirios Kalpadakis, Christina Katodritou, Eirini Leonidopoulou, Theoni others

Published
2021

8. Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies

Author

Vassilakopoulos, Theodoros P. Asimakopoulos, John V. and Konstantopoulos, Kostas Angelopoulou, Maria K. and Vassilakopoulos, Theodoros P. Asimakopoulos, John V. and Konstantopoulos, Kostas Angelopoulou, Maria K.

Abstract

The outcome of patients with relapsed/refractory classical Hodgkin lymphoma (rr-cHL) has improved considerably in recent years owing to the approval of highly active novel agents such as brentuximab vedotin and Programmed Death-1 (PD-1) inhibitors. Although no randomized trials have been conducted to provide formal proof, it is almost undisputable that the survival of these patients has been prolonged. As autologous stem-cell transplantation (SCT) remains the standard of care for second-line therapy of most patients with rr-cHL, optimization of second-line regimens with the use of brentuximab vedotin, or, in the future, checkpoint inhibitors, is promising to increase both the eligibility rate for transplant and the final outcome. The need for subsequent therapy, and especially allogeneic SCT, can be reduced with brentuximab vedotin consolidation for 1 year, while pembrolizumab is also being tested in this setting. Several other drug categories appear to be active in rr-cHL, but their development has been delayed by the appearance of brentuximab vedotin, nivolumab and pembrolizumab, which have dominated the field of rr-cHL treatment in the last 5 years. Combinations of active drugs in chemo-free approaches may further increase efficacy and hopefully reduce toxicity in rr-cHL, but are still under development.

Published
2020

9. Evaluation of automated capillary complete blood counts for routine clinical decision making in a large cohort of hematological patients, using Mindray BC-3000 Plus Auto and Sysmex XE-5000 hematology analyzers

Author

Oudatzis, Georgios Tsagarakis, Nikolaos J. Paterakis, Georgios and Vasileiou, Paraskevi Xenou, Efthalia Maraki, Paraskevi and Pangrati, Toula Angelopoulou, Maria K. Vassilakopoulos, Theodoros P. Konstantopoulos, Kostas and Oudatzis, Georgios Tsagarakis, Nikolaos J. Paterakis, Georgios and Vasileiou, Paraskevi Xenou, Efthalia Maraki, Paraskevi and Pangrati, Toula Angelopoulou, Maria K. Vassilakopoulos, Theodoros P. Konstantopoulos, Kostas

Abstract

Introduction Venous blood (VB) sampling for complete blood count (CBC) via venipuncture is the basic method for the daily evaluation of hematological patients. However, several issues during this process, such as venipuncture difficulty and repetitive attempts, may cause pain, phlebitis, hematomas, inadequate sampling, and patient discomfort. Capillary blood (CB) sampling could be an alternative and less painful solution for the patient. The purpose of this study was the comparative evaluation of basic CBC parameters, as counted from venous and capillary blood samples. Methods During the period 06/2016-06/2019 in which the study was conducted, 1634 automated counts of VB or CB were performed, derived from 425 hematological hospitalized patients. Bland-Altman plots were performed to show the agreement of VB and CB counts of common hematological parameters (Hb, Hct, WBC, absolute neutrophil count-[ANC], RBC, Plt, MCV, MCH), using two different hematology analyzers (Mindray BC-3000 Plus Auto and Sysmex XE-5000). Clinical significance of CB sampling was assessed by applying specific clinically significant cutoffs for Hb, ANC, and Plt. Results All measured parameters revealed a significant correlation (r > .9) between CB and VB samples, irrelatively of the hematology analyzer used. CB measurements of Hb, ANC, and Plt, at different clinically important cutoff levels, showed excellent sensitivity (87%-100%), specificity (95%-100%), positive predictive value, and negative predictive value (87%-100% and 90%-100%, respectively). Conclusion Capillary blood and VB counts in hematological patients were equivalent for most basic hematological parameters. Hb, ANC, and Plt CB counts revealed clinically significant performance, indicating that they can reliably substitute VB sampling in the day work.

Published
2020

10. Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study

Author

Terpos, Evangelos Fotiou, Despina Anargyrou, Konstantinos and Vassilakopoulos, Theodoros P. Christoulas, Dimitrios Makras, Polyzois Dimou, Maria Ntanasis-Stathopoulos, Ioannis and Masouridou, Stavroula Angelopoulou, Maria K. Papatheodorou, Athanasios Tsionos, Konstantinos Panayiotidis, Panayiotis and Dimopoulos, Meletios A. and Terpos, Evangelos Fotiou, Despina Anargyrou, Konstantinos and Vassilakopoulos, Theodoros P. Christoulas, Dimitrios Makras, Polyzois Dimou, Maria Ntanasis-Stathopoulos, Ioannis and Masouridou, Stavroula Angelopoulou, Maria K. Papatheodorou, Athanasios Tsionos, Konstantinos Panayiotidis, Panayiotis and Dimopoulos, Meletios A.

Published
2019

11. Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece

Author

Symeonidis, Argiris Papageorgiou, Sotirios Patrinos, Antonis and Melachrinou, Maria Kourakli, Alexandra Pappa, Vassiliki and Angelopoulou, Maria K. Sioni, Anastasia Kanellias, Nikolaos and Chatzileontiadou, Sofia Hatzimichael, Eleftheria Zikos, Panagiotis Pouli, Anastasia Papaioannou, Maria Terpos, Evangelos Pangalis, Gerasimos Vassilakopoulos, Theodoros P. and Symeonidis, Argiris Papageorgiou, Sotirios Patrinos, Antonis and Melachrinou, Maria Kourakli, Alexandra Pappa, Vassiliki and Angelopoulou, Maria K. Sioni, Anastasia Kanellias, Nikolaos and Chatzileontiadou, Sofia Hatzimichael, Eleftheria Zikos, Panagiotis Pouli, Anastasia Papaioannou, Maria Terpos, Evangelos Pangalis, Gerasimos Vassilakopoulos, Theodoros P.

Published
2019

12. Central nervous system involvement in primary bone marrow or splenic marginal zone lymphoma: Report of two cases and review of the literature

Author

Angelopoulou, Maria K. Vassilakopoulos, Theodoros P. and Konstantinou, Eliana Boutsikas, George Asimakopoulos, John V. and Triantafyllou, Evangelia-Faidra Petevi, Kyriaki and Kanellopoulos, Alexandros Moschogiannis, Maria Pangalis, Gerassimos A. Siakantaris, Marina P. Konstantopoulos, Kostas and Angelopoulou, Maria K. Vassilakopoulos, Theodoros P. and Konstantinou, Eliana Boutsikas, George Asimakopoulos, John V. and Triantafyllou, Evangelia-Faidra Petevi, Kyriaki and Kanellopoulos, Alexandros Moschogiannis, Maria Pangalis, Gerassimos A. Siakantaris, Marina P. Konstantopoulos, Kostas

Published
2019

13. Low bone mineral density and high bone turnover in patients with Non-Hodgkin's Lymphoma (NHL) who receive frontline therapy: results of a multicenter prospective study

Author

Anargyrou, Konstantinos Fotiou, Despina Vassilakopoulos, Theodoros P Christoulas, Dimitrios Makras, Polyzois Dimou, Maria Ntanasis-Stathopoulos, Ioannis Masouridou, Stavroula Angelopoulou, Maria K Papatheodorou, Athanasios others and Anargyrou, Konstantinos Fotiou, Despina Vassilakopoulos, Theodoros P Christoulas, Dimitrios Makras, Polyzois Dimou, Maria Ntanasis-Stathopoulos, Ioannis Masouridou, Stavroula Angelopoulou, Maria K Papatheodorou, Athanasios others

Published
2019

14. Low bone mineral density and high bone turnover in patients with Non-Hodgkin's Lymphoma (NHL) who receive frontline therapy: results of a multicenter prospective study

Author

Anargyrou, Konstantinos Fotiou, Despina Vassilakopoulos, Theodoros P Christoulas, Dimitrios Makras, Polyzois Dimou, Maria Ntanasis-Stathopoulos, Ioannis Masouridou, Stavroula Angelopoulou, Maria K Papatheodorou, Athanasios others and Anargyrou, Konstantinos Fotiou, Despina Vassilakopoulos, Theodoros P Christoulas, Dimitrios Makras, Polyzois Dimou, Maria Ntanasis-Stathopoulos, Ioannis Masouridou, Stavroula Angelopoulou, Maria K Papatheodorou, Athanasios others

Published
2019

15. Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in Real-Life Outside of Clinical Trials

Author

Sachanas, Sotirios, Pangalis, Gerassimos A., Fink, Anna-Maria, Bahlo, Jasmin, Fischer, Kirsten, Levidou, Georgia, Kyrtsonis, Marie-Christine, Bartzi, Vassiliki, Vassilakopoulos, Theodoros P., Kalpadakis, Christina, Koulieris, Efstathios, Moschogiannis, Maria, Yiakoumis, Xanthi, Tsirkinidis, Pantelis, Angelopoulou, Maria K., Eichhorst, Barbara, Hallek, Michael, Sachanas, Sotirios, Pangalis, Gerassimos A., Fink, Anna-Maria, Bahlo, Jasmin, Fischer, Kirsten, Levidou, Georgia, Kyrtsonis, Marie-Christine, Bartzi, Vassiliki, Vassilakopoulos, Theodoros P., Kalpadakis, Christina, Koulieris, Efstathios, Moschogiannis, Maria, Yiakoumis, Xanthi, Tsirkinidis, Pantelis, Angelopoulou, Maria K., Eichhorst, Barbara, and Hallek, Michael

Abstract

Background: Only few studies have focused exclusively on patients with small lymphocytic lymphoma (SLL). Patients and Methods: In the present report, 103 SLL patients were analyzed from both, clinical trials of the German Chronic Lymphocytic Leukemia Study Group and Greek centers, and emphasis was placed on the therapeutic strategy. The impact of lymph node characteristics, such as the presence of proliferation centers (PCs) on response and survival was also assessed. Results: SLL patients included in clinical trials were treated mostly with fludarabine-based regimens while those in reallife were staged and treated mostly as patients with low-grade lymphomas. Our analysis showed a trend for better survival for patients with SLL without detectable PCs. Conclusion: Patients with SLL outside of clinical trials are usually treated as cases of lymphoma. In addition, this analysis supports published data regarding the adverse prognostic value of the presence of PCs in lymphoid nodes in SLL.

Published
2019

16. Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in Real-Life Outside of Clinical Trials

Author

Sachanas, Sotirios, Pangalis, Gerassimos A., Fink, Anna-Maria, Bahlo, Jasmin, Fischer, Kirsten, Levidou, Georgia, Kyrtsonis, Marie-Christine, Bartzi, Vassiliki, Vassilakopoulos, Theodoros P., Kalpadakis, Christina, Koulieris, Efstathios, Moschogiannis, Maria, Yiakoumis, Xanthi, Tsirkinidis, Pantelis, Angelopoulou, Maria K., Eichhorst, Barbara, Hallek, Michael, Sachanas, Sotirios, Pangalis, Gerassimos A., Fink, Anna-Maria, Bahlo, Jasmin, Fischer, Kirsten, Levidou, Georgia, Kyrtsonis, Marie-Christine, Bartzi, Vassiliki, Vassilakopoulos, Theodoros P., Kalpadakis, Christina, Koulieris, Efstathios, Moschogiannis, Maria, Yiakoumis, Xanthi, Tsirkinidis, Pantelis, Angelopoulou, Maria K., Eichhorst, Barbara, and Hallek, Michael

Abstract

Background: Only few studies have focused exclusively on patients with small lymphocytic lymphoma (SLL). Patients and Methods: In the present report, 103 SLL patients were analyzed from both, clinical trials of the German Chronic Lymphocytic Leukemia Study Group and Greek centers, and emphasis was placed on the therapeutic strategy. The impact of lymph node characteristics, such as the presence of proliferation centers (PCs) on response and survival was also assessed. Results: SLL patients included in clinical trials were treated mostly with fludarabine-based regimens while those in reallife were staged and treated mostly as patients with low-grade lymphomas. Our analysis showed a trend for better survival for patients with SLL without detectable PCs. Conclusion: Patients with SLL outside of clinical trials are usually treated as cases of lymphoma. In addition, this analysis supports published data regarding the adverse prognostic value of the presence of PCs in lymphoid nodes in SLL.

Published
2019

17. Prognostic factors in Hodgkin lymphoma

Author

Broeckelmann, Paul J., Angelopoulou, Maria K., Vassilakopoulos, Theodoros P., Broeckelmann, Paul J., Angelopoulou, Maria K., and Vassilakopoulos, Theodoros P.

Abstract

During the last decades, the prognosis of Hodgkin lymphoma (HL) has been improved significantly with the introduction of effective chemotherapy and the implementation of risk-adapted treatment approaches. Identification of reliable risk factors is crucial to guide treatment over the course of disease. Both clinical and biological factors have been implicated in the prognosis of HL and are often used in prognostic scores to discriminate risk groups. To prevent under- or overtreatment, patients are usually assigned to one of the three widely established risk groups for first-line treatment, based solely on clinical risk factors. To further individualize therapeutic approaches, functional imaging with positron emission tomography (PET) is becoming more widely implemented and precisely investigated within clinical trials. Biological prognostic factors have been widely evaluated but are still not a part of standard prognostication. This review will discuss the currently established factors and risk models at first diagnosis and in the setting of relapsed/refractory disease and also focus on biological factors and PET, summarizing current standards and future perspectives. (C) 2016 Elsevier Inc. All rights reserved.

Published
2016

18. Prognostic factors in Hodgkin lymphoma

Author

Broeckelmann, Paul J., Angelopoulou, Maria K., Vassilakopoulos, Theodoros P., Broeckelmann, Paul J., Angelopoulou, Maria K., and Vassilakopoulos, Theodoros P.

Abstract

During the last decades, the prognosis of Hodgkin lymphoma (HL) has been improved significantly with the introduction of effective chemotherapy and the implementation of risk-adapted treatment approaches. Identification of reliable risk factors is crucial to guide treatment over the course of disease. Both clinical and biological factors have been implicated in the prognosis of HL and are often used in prognostic scores to discriminate risk groups. To prevent under- or overtreatment, patients are usually assigned to one of the three widely established risk groups for first-line treatment, based solely on clinical risk factors. To further individualize therapeutic approaches, functional imaging with positron emission tomography (PET) is becoming more widely implemented and precisely investigated within clinical trials. Biological prognostic factors have been widely evaluated but are still not a part of standard prognostication. This review will discuss the currently established factors and risk models at first diagnosis and in the setting of relapsed/refractory disease and also focus on biological factors and PET, summarizing current standards and future perspectives. (C) 2016 Elsevier Inc. All rights reserved.

Published
2016

20. Clonal B-cell lymphocytosis exhibiting immunophenotypic features consistent with a marginal-zone origin : is this a distinct entity?

Author

Xochelli, Aliki, Kalpadakis, Christina, Gardiner, Anne, Baliakas, Panagiotis, Vassilakopoulos, Theodoros P., Mould, Sarah, Davis, Zadie, Stalika, Evangelia, Kanellis, George, Angelopoulou, Maria K., McIver-Brown, Neil, Ibbotson, Rachel, Sachanas, Sotirios, Korkolopoulou, Penelope, Athanasiadou, Anastasia, Anagnostopoulos, Achilles, Papadaki, Helen A., Papadaki, Theodora, Stamatopoulos, Kostas, Pangalis, Gerassimos A., Oscier, David, Xochelli, Aliki, Kalpadakis, Christina, Gardiner, Anne, Baliakas, Panagiotis, Vassilakopoulos, Theodoros P., Mould, Sarah, Davis, Zadie, Stalika, Evangelia, Kanellis, George, Angelopoulou, Maria K., McIver-Brown, Neil, Ibbotson, Rachel, Sachanas, Sotirios, Korkolopoulou, Penelope, Athanasiadou, Anastasia, Anagnostopoulos, Achilles, Papadaki, Helen A., Papadaki, Theodora, Stamatopoulos, Kostas, Pangalis, Gerassimos A., and Oscier, David

Abstract

The biological and clinical significance of a clonal B-cell lymphocytosis with an immunophenotype consistent with marginal-zone origin (CBL-MZ) is poorly understood. We retrospectively evaluated 102 such cases with no clinical evidence to suggest a concurrent MZ lymphoma. Immunophenotyping revealed a clonal B-cell population with Matutes score <= 2 in all cases; 19/102 were weakly CD5 positive and all 35 cases tested expressed CD49d. Bone marrow biopsy exhibited mostly mixed patterns of small B-lymphocytic infiltration. A total of 48/66 (72.7%) cases had an abnormal karyotype. Immunogenetics revealed overusage of the IGHV4-34 gene and somatic hypermutation in 71/79 (89.8%) IGHV-IGHD-IGHJ gene rearrangements. With a median follow-up of 5 years, 85 cases remain stable (group A), whereas 17 cases (group B) progressed, of whom 15 developed splenomegaly. The clonal B-cell count, degree of marrow infiltration, immunophenotypic, or immunogenetic findings at diagnosis did not distinguish between the 2 groups. However, deletions of chromosome 7q were confined to group A and complex karyotypes were more frequent in group B. Although CBL-MZ may antedate SMZL/SLLU, most cases remain stable over time. These cases, not readily classifiable within the World Heath Organization classification, raise the possibility that CBL-MZ should be considered as a new provisional entity within the spectrum of clonal MZ disorders.

Published
2014
Full Text
View/download PDF

21. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab

Author

Papageorgiou, Sotirios G Diamantopoulos, Panayiotis Levidou, Georgia Angelopoulou, Maria K Economopoulou, Panagiota Efthimiou, Anna Constantinou, Nikos Katsigiannis, Andreas Korkolopoulou, Penelope Pappa, Vassiliki others and Papageorgiou, Sotirios G Diamantopoulos, Panayiotis Levidou, Georgia Angelopoulou, Maria K Economopoulou, Panagiota Efthimiou, Anna Constantinou, Nikos Katsigiannis, Andreas Korkolopoulou, Penelope Pappa, Vassiliki others

Published
2013

22. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab

Author

Papageorgiou, Sotirios G Diamantopoulos, Panayiotis Levidou, Georgia Angelopoulou, Maria K Economopoulou, Panagiota Efthimiou, Anna Constantinou, Nikos Katsigiannis, Andreas Korkolopoulou, Penelope Pappa, Vassiliki others and Papageorgiou, Sotirios G Diamantopoulos, Panayiotis Levidou, Georgia Angelopoulou, Maria K Economopoulou, Panagiota Efthimiou, Anna Constantinou, Nikos Katsigiannis, Andreas Korkolopoulou, Penelope Pappa, Vassiliki others

Published
2013

23. Significance of Serum Free Light Chains in Chronic Lymphocytic Leukemia (cll) Prognosis

Author

Sarris, Katerina Bartzis, Vassiliki Maltezas, Dimitris and Koulieris, Efstathios Tzenou, Tatiana Sachanas, Sotirios P. and Nikolaou, Eftychia Efthymiou, Anna Bitsani, Katerina Dimou, Maria Vassilakopoulos, Theodoros Siakantaris, Marina and Angelopoulou, Maria K. Kontopidou, Flora Tsaftaridis, Panagiotis and Kafasi, Nikolitsa Pangalis, Gerassimos A. Panayiotidis, Panayiotis Harding, Stephen Kyrtsonis, Marie-Christine and Sarris, Katerina Bartzis, Vassiliki Maltezas, Dimitris and Koulieris, Efstathios Tzenou, Tatiana Sachanas, Sotirios P. and Nikolaou, Eftychia Efthymiou, Anna Bitsani, Katerina Dimou, Maria Vassilakopoulos, Theodoros Siakantaris, Marina and Angelopoulou, Maria K. Kontopidou, Flora Tsaftaridis, Panagiotis and Kafasi, Nikolitsa Pangalis, Gerassimos A. Panayiotidis, Panayiotis Harding, Stephen Kyrtsonis, Marie-Christine

Published
2012

24. A Comprehensive Immunohistochemical Approach of AKT/mTOR Pathway and p-STAT3 in Mycosis Fungoides.

Author

Siakantaris, Marina Levidou, Georgia Papadaki, Theodora and Papadavid, Evangelia Vassilakopoulos, Theodoros P. Angelopoulou, Maria K. Marinos, Leonidas Nikolaou, Vassiliki Economidi, Aphrodite Antoniou, Christina Patsouris, Efstratios and Pangalis, G. A. Korkolopoulou, Penelope and Siakantaris, Marina Levidou, Georgia Papadaki, Theodora and Papadavid, Evangelia Vassilakopoulos, Theodoros P. Angelopoulou, Maria K. Marinos, Leonidas Nikolaou, Vassiliki Economidi, Aphrodite Antoniou, Christina Patsouris, Efstratios and Pangalis, G. A. Korkolopoulou, Penelope

Published
2012

25. Increased Serum Transforming Growth Factor-beta1 (Tgf-beta1) Is Related to a Better Outcome in MM, WM and CLL Patients

Author

Maltezas, Dimitrios Sarris, Katerina Koulieris, Efstathios and Tzenou, Tatiana Bartzis, Vassiliki Nikolaou, Eftychia and Gavriatopoulou, Maria Dimou, Maria Terpos, Evangelos and Angelopoulou, Maria K. Vassilakopoulos, Theodoros P. and Panayiotidis, Panayiotis Pangalis, Gerasimos Dimopoulos, Meletios A. Kyrtsonis, Marie-Christine and Maltezas, Dimitrios Sarris, Katerina Koulieris, Efstathios and Tzenou, Tatiana Bartzis, Vassiliki Nikolaou, Eftychia and Gavriatopoulou, Maria Dimou, Maria Terpos, Evangelos and Angelopoulou, Maria K. Vassilakopoulos, Theodoros P. and Panayiotidis, Panayiotis Pangalis, Gerasimos Dimopoulos, Meletios A. Kyrtsonis, Marie-Christine

Published
2012

26. Lower Levels of Survivin in Patients with Leukemic Low Grade B-Cell Lymphomas Expressing LMP1 Oncoprotein of Epstein-Barr Virus

Author

Diamantopoulos, Panagiotis Theodorou Polonyphi, Katerina and Sofotasioiu, Maria Galanopoulos, Athanassios Spanakis, Nikolaos and Rassidakis, George Kouzis, Panagiotis Papadopoulou, Vassiliki Kalala, Fani Iliakis, Theodoros Vassilakopoulos, Theodoros Angelopoulou, Maria K. Siakantaris, Marina Terpos, Evangelos Variami, Eleni Kollia, Panagoula Pangalis, Gerassimos A. Viniou, Nora-Athina and Diamantopoulos, Panagiotis Theodorou Polonyphi, Katerina and Sofotasioiu, Maria Galanopoulos, Athanassios Spanakis, Nikolaos and Rassidakis, George Kouzis, Panagiotis Papadopoulou, Vassiliki Kalala, Fani Iliakis, Theodoros Vassilakopoulos, Theodoros Angelopoulou, Maria K. Siakantaris, Marina Terpos, Evangelos Variami, Eleni Kollia, Panagoula Pangalis, Gerassimos A. Viniou, Nora-Athina

Published
2012

27. Impact of Novel M-Component Based Biomarkers On to Progression Free Survival After Treatment in Intact Immunoglobulin Multiple Myeloma

Author

Koulieris, Efstathios Maltezas, Dimitrios Eytychia, Nikolaou and Bartzis, Vassiliki Tzenou, Tatianna Karali, Vassiliki Ilias, Pessach Sarris, Katerina Harding, Stephen Bradwell, Arthur and Vassilakopoulos, Theodoros P. Angelopoulou, Maria K. Kafasi, Nikolitsa Panayiotidis, Panayiotis Kyrtsonis, Marie-Christine and Koulieris, Efstathios Maltezas, Dimitrios Eytychia, Nikolaou and Bartzis, Vassiliki Tzenou, Tatianna Karali, Vassiliki Ilias, Pessach Sarris, Katerina Harding, Stephen Bradwell, Arthur and Vassilakopoulos, Theodoros P. Angelopoulou, Maria K. Kafasi, Nikolitsa Panayiotidis, Panayiotis Kyrtsonis, Marie-Christine

Published
2012

28. A Shorter Time to First Treatment and Worst Overall survival Is Observed in Cll Patients with Reduced Serum IgM As Evaluated with Novel Serum Immunoassays

Author

Koulieris, Efstathios Sarris, Katerina Kafasi, Nikolitsa and Bartzis, Vassiliki Tzenou, Tatiana Maltezas, Dimitrios and Sachanas, Sotirios P. Efthymiou, Anna Mpitsanis, Katerina and Vardounioti, Ioanna Dimou, Maria Vassilakopoulos, Theodoros P. and Siakantaris, Marina Angelopoulou, Maria K. Tsaftaridis, Panagiotis Mparmparousis, Despoina Matsouka, Charis and Pangalis, Gerasimos Panayiotidis, Panayiotis Kyrtsonis, Marie-Christine and Koulieris, Efstathios Sarris, Katerina Kafasi, Nikolitsa and Bartzis, Vassiliki Tzenou, Tatiana Maltezas, Dimitrios and Sachanas, Sotirios P. Efthymiou, Anna Mpitsanis, Katerina and Vardounioti, Ioanna Dimou, Maria Vassilakopoulos, Theodoros P. and Siakantaris, Marina Angelopoulou, Maria K. Tsaftaridis, Panagiotis Mparmparousis, Despoina Matsouka, Charis and Pangalis, Gerasimos Panayiotidis, Panayiotis Kyrtsonis, Marie-Christine

Published
2012

29. Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib

Author

Anargyrou, Konstantinos Terpos, Evangelos Vassilakopoulos, Theodoros P Pouli, Anastasia Sachanas, Sotirios Tzenou, Tatiana Masouridis, Stavroula Christoulas, Dimitrios Angelopoulou, Maria K Dimitriadou, Evangelia M others and Anargyrou, Konstantinos Terpos, Evangelos Vassilakopoulos, Theodoros P Pouli, Anastasia Sachanas, Sotirios Tzenou, Tatiana Masouridis, Stavroula Christoulas, Dimitrios Angelopoulou, Maria K Dimitriadou, Evangelia M others

Published
2008

30. Jumping translocations in hematological malignancies: a cytogenetic study of five cases

Author

Mancila, Kalliopi N. Georgakakos, Vasileios N. Stavropoulou, Chryssa Spyridonidis, Alexandros Angelopoulou, Maria K. and Vlachadami, Ioanna Katsigiannis, Andreas Roussou, Paraskevi and Pantelias, Gabriel E. Sambani, Constantina and Mancila, Kalliopi N. Georgakakos, Vasileios N. Stavropoulou, Chryssa Spyridonidis, Alexandros Angelopoulou, Maria K. and Vlachadami, Ioanna Katsigiannis, Andreas Roussou, Paraskevi and Pantelias, Gabriel E. Sambani, Constantina

Abstract

Jumping translocations (JT) are rare cytogenetic aberrations in hematological malignancies that include unbalanced translocations involving a donor chromosome arm or chromosome segment that has fused to two or more different recipient chromosomes in different cell lines. We report five cases associated with different hematologic disorders and JT to contribute to the investigation of the origin, pathogenesis, and clinical significance of JT These cases involve JT of 1q in a ease of acute myeloblastic leukemia (AML)-M1, a case of Burkitt lymphoma, and a case of BCR/ABL-positive acute lymphoblastic leukemia, as well as a JT of 13q in a case of AML-M5, and a JT of 11q segment in a case of undifferentiated leukemia. TO Our knowledge, with regard to hematologic malignancies, this study presents the first case of JT associated with AML-M1, the first case of JT involving 13q as a donor chromosome, and the first report of JT involving a segment of 11q containing two copies of the MLL gene, jumping on to two recipient chromosomes in each cell line and resulting in six copies of the MLL gene. Our investigation suggests that JT may not contribute to the pathogenesis but rather to the progression of the disease, and it demonstrates that chromosome band 1q10 as a breakpoint of the donor chromosome 1q is also implicated in AML, not. only in multiple myeloma as it has been known until now. (C) 2008 Elsevier Inc. All rights reserved.

Published
2008

31. Non-gastric extra-nodal marginal zone lymphomas-a single centre experience on 76 patients

Author

Kalpadakis, Christina Pangalis, Gerassimos A. Vassilakopoulos, Theodoros P. Kyrtsonis, Maria-Christina Siakantaris, Marina P. and Kontopidou, Flora N. Korkolopoulou, Penelope Bobotsis, Panagia Sahanas, Sotirios Tzenou, Tatiana Anagnostou, Dimitra Dimitriadou, Evangelia Yiakoumis, Xanthi Patsouris, Evangelos Roussou, Panagiota Panayiotidis, Panayiotis and Papadaki, Eleni Angelopoulou, Maria K. and Kalpadakis, Christina Pangalis, Gerassimos A. Vassilakopoulos, Theodoros P. Kyrtsonis, Maria-Christina Siakantaris, Marina P. and Kontopidou, Flora N. Korkolopoulou, Penelope Bobotsis, Panagia Sahanas, Sotirios Tzenou, Tatiana Anagnostou, Dimitra Dimitriadou, Evangelia Yiakoumis, Xanthi Patsouris, Evangelos Roussou, Panagiota Panayiotidis, Panayiotis and Papadaki, Eleni Angelopoulou, Maria K.

Abstract

In the present study, we assessed the clinical and pathological data of 76 patients with the diagnosis of non-gastric extranodal marginal zone B-cell lymphoma. The most commonly affected sites were salivary glands, skin, ocular adnexa, lung, intestine and Waldeyer’s ring. Ann Arbor stage I disease was present in 39 patients (51%), stage II in 10 (13%) and stage IV in 27 (36%). In 17 cases (21%), the lymphoma presented at multiple mucosal sites. Lymph node and bone marrow involvement were present in 21% and 16%, respectively. Most cases were in the low or low-intermediate risk group. Treatment was heterogeneous and included chlorambucil in 59% either alone or in combination with other agents. Complete and partial remission was achieved in 79% and 7%, respectively, with an overall response rate of 86%. The 5- and 10-year overall survival and cause-specific survival rates were 94%, 82% and 95%, 91%, respectively. The 5- and 10-year progression free survival was 56% and 41%, respectively. The only feature associated with inferior outcome was disease localisation to the lung.

Published
2008

32. Outcome and toxicity in relapsed hairy cell leukemia patients treated with rituximab

Author

Angelopoulou, Maria K. Pangalis, Gerassimos A. Sachanas, Sotirios Kokoris, Styliani I. Anargyrou, Konstantinos and Galani, Zaharoula Kalpadakis, Christina Vassilakopoulos, Theodoros P. and Angelopoulou, Maria K. Pangalis, Gerassimos A. Sachanas, Sotirios Kokoris, Styliani I. Anargyrou, Konstantinos and Galani, Zaharoula Kalpadakis, Christina Vassilakopoulos, Theodoros P.

Published
2008

33. Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib

Author

Anargyrou, Konstantinos Terpos, Evangelos Vassilakopoulos, Theodoros P Pouli, Anastasia Sachanas, Sotirios Tzenou, Tatiana Masouridis, Stavroula Christoulas, Dimitrios Angelopoulou, Maria K Dimitriadou, Evangelia M others and Anargyrou, Konstantinos Terpos, Evangelos Vassilakopoulos, Theodoros P Pouli, Anastasia Sachanas, Sotirios Tzenou, Tatiana Masouridis, Stavroula Christoulas, Dimitrios Angelopoulou, Maria K Dimitriadou, Evangelia M others

Published
2008

34. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma

Author

Kyrtsonis, Marie-Christine Vassilakopoulos, Theodoros P. Kafasi, Nicoletta Sachanas, Sotirios Tzenou, Tatiana Papadogiannis, Argiroula Galanis, Zacharoula Kalpadakis, Christina Dimou, Maria Kyriakou, Elias Angelopoulou, Maria K. Dimopoulou, Maria N. Siakantaris, Marina P. Dimitriadou, Evangelia M. and Kokoris, Styliani I. Panayiotidis, Panayiotis Pangalis, Gerassimos A. and Kyrtsonis, Marie-Christine Vassilakopoulos, Theodoros P. Kafasi, Nicoletta Sachanas, Sotirios Tzenou, Tatiana Papadogiannis, Argiroula Galanis, Zacharoula Kalpadakis, Christina Dimou, Maria Kyriakou, Elias Angelopoulou, Maria K. Dimopoulou, Maria N. Siakantaris, Marina P. Dimitriadou, Evangelia M. and Kokoris, Styliani I. Panayiotidis, Panayiotis Pangalis, Gerassimos A.

Abstract

The prognostic value of baseline serum free light chain ratio (sFLCR) was investigated in 94 multiple myeloma (MM) patients. sFLCR was calculated as kappa/lambda or lambda/kappa, depending on the patients’ dominating monoclonal light chain. Median baseline sFLCR was 3.57 in kappa-MM patients, 45.09 in lambda-MM. ‘High’ sFLCR (>= the observed median value for kappa- and lambda-MM respectively) correlated with elevated serum creatinine and lactate dehydrogenase, extensive marrow infiltration and light chain type MM. The 5-year disease-specific survival was 82% and 30% in patients with sFLCR lower than and equal or greater than the median, respectively (P = 0.0001). sFLCR was an independent prognostic factor.

Published
2007

35. Serum free light chain ratio (FLCR) at diagnosis constitute a powerful prognostic factor of survival in multiple myeloma (MM).

Author

Kyrtsonis, Marie-Christine Vassilakopoulos, Theodoros P. Kafasi, Nicoletta Sachanas, Sotirios Tzenou, Tatiana Papadogiannis, Argiroula Galanis, Zacharoula Kalpadakis, Christina Dimou, Maria Kyriakou, Elias Angelopoulou, Maria K. Dimopoulou, Maria N. Siakantaris, Marina P. Kokoris, Styliam I. and Dimitriadou, Evangelia M. Panayiotidis, Panayiotis Pangalis, Gerassimos A. and Kyrtsonis, Marie-Christine Vassilakopoulos, Theodoros P. Kafasi, Nicoletta Sachanas, Sotirios Tzenou, Tatiana Papadogiannis, Argiroula Galanis, Zacharoula Kalpadakis, Christina Dimou, Maria Kyriakou, Elias Angelopoulou, Maria K. Dimopoulou, Maria N. Siakantaris, Marina P. Kokoris, Styliam I. and Dimitriadou, Evangelia M. Panayiotidis, Panayiotis Pangalis, Gerassimos A.

Published
2006

36. Rituximab-CHOP (R-CHOP) and radiotherapy (RT) for primary mediastinal large B-cell lymphoma (PMLBCL).

Author

Vassilakopoulos, Theodores P. Angelopoulou, Maria K. Galani, Zacharoula Sachanas, Sotirios Katsigiannis, Andreas and Vrakidou, Effimia Poziopoulos, Christos Constantinou, Nikos and Repoussis, Panayiotis Dimopoulou, Maria N. Kokoris, Stiliani I. and Michali, Evridiki Dimitriadou, Evangelia M. Siakantaris, Marina P. Kontopidou, Flora N. Kalpadaki, Christina Viniou, Nora-Athina Kyriakou, Elias Korkolopoulou, Penelope and Kyrtsonis, Marie-Christine Panayiotidis, Panayiotis Roussou, Paraskevi Pangalis, Gerassimos A. and Vassilakopoulos, Theodores P. Angelopoulou, Maria K. Galani, Zacharoula Sachanas, Sotirios Katsigiannis, Andreas and Vrakidou, Effimia Poziopoulos, Christos Constantinou, Nikos and Repoussis, Panayiotis Dimopoulou, Maria N. Kokoris, Stiliani I. and Michali, Evridiki Dimitriadou, Evangelia M. Siakantaris, Marina P. Kontopidou, Flora N. Kalpadaki, Christina Viniou, Nora-Athina Kyriakou, Elias Korkolopoulou, Penelope and Kyrtsonis, Marie-Christine Panayiotidis, Panayiotis Roussou, Paraskevi Pangalis, Gerassimos A.

Published
2006

37. Serum ferritin levels in previously untreated classical Hodgkin lymphoma: correlations and prognostic significance

Author

Karakatsanis, Stamatios Panitsas, Fotios Arapaki, Maria and Galopoulos, Dimitrios Asimakopoulos, V, John Liaskas, Athanassios Chatzidimitriou, Chrysovalantou Belia, Marina and Konstantinou, Elianna Vassilopoulos, Ioannis Papadatos, Stamatis S. Sachanas, Sotirios Efstathopoulou, Maria Yiakoumis, Xanthoula Pardalis, Vassilios Iliakis, Theodoros and Giannakopoulou, Nefeli Dimou, Maria Chatzidavid, Sevastianos and Boutsikas, George Petevi, Kyriaki Kanellopoulos, Alexandros and Gainaru, Gabriella Variamis, Eleni Siakantaris, Marina P. and Kyrtsonis, Marie-Christine Plata, Eleni Tsaftaridis, Panayiotis and Dimopoulou, Maria N. Viniou, Nora-Athina Syrigos, Konstantinos N. Pangalis, Gerassimos A. Panayiotidis, Panayiotis and Konstantopoulos, Kostas Angelopoulou, Maria K. and Vassilakopoulos, Theodoros P. and Karakatsanis, Stamatios Panitsas, Fotios Arapaki, Maria and Galopoulos, Dimitrios Asimakopoulos, V, John Liaskas, Athanassios Chatzidimitriou, Chrysovalantou Belia, Marina and Konstantinou, Elianna Vassilopoulos, Ioannis Papadatos, Stamatis S. Sachanas, Sotirios Efstathopoulou, Maria Yiakoumis, Xanthoula Pardalis, Vassilios Iliakis, Theodoros and Giannakopoulou, Nefeli Dimou, Maria Chatzidavid, Sevastianos and Boutsikas, George Petevi, Kyriaki Kanellopoulos, Alexandros and Gainaru, Gabriella Variamis, Eleni Siakantaris, Marina P. and Kyrtsonis, Marie-Christine Plata, Eleni Tsaftaridis, Panayiotis and Dimopoulou, Maria N. Viniou, Nora-Athina Syrigos, Konstantinos N. Pangalis, Gerassimos A. Panayiotidis, Panayiotis and Konstantopoulos, Kostas Angelopoulou, Maria K. and Vassilakopoulos, Theodoros P.

Abstract

Serum ferritin (SF) is frequently elevated in classical Hodgkin lymphoma (cHL). We report on its prognostic significance in an unselected series of 529 cHL patients treated with state-of-the-art therapy. Higher baseline levels correlated with markers of advanced/aggressive disease. SF levels were significantly higher in male and older patients, those with high body mass index and mixed cellularity histology. The strongest correlation was recorded between SF and complement reactive protein (CRP) levels. Gender-specific SF cutoffs which provided the best discrimination in terms of freedom from progression (FFP) were identified. In multivariate analysis elevated SF levels, advanced stage and high lactate dehydrogenase (LDH) were independent prognostic factors of inferior FFP. SF also appears to retain independent prognostic significance for progression-free survival (PFS) but not for overall survival (OS). In conclusion, SF levels in cHL reflect disease activity and are associated with adverse patient outcomes.

Catalog

Books, media, physical & digital resources
See catalog results